Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/632,706 Filing Date 8-1-2003 INFORMATION DISCLOSURE First Named Inventor Marks, et al STATEMENT BY APPLICANT Art Unit 1645 (Use as many sheets as necessary) Examiner Name Minnifield, Nita M UCSF-400CIP Attorney Docket Number

Sheet 1 U. S. PATENT DOCUMENTS Pages, Columns, Lines, Where Name of Patentee or Cite No.1 Document Number Publication Date Examiner Relevant Passages or Relevant Applicant of Cited Document MM-DD-YYYY Initials\* Figures Appear Number-Kind Code<sup>2 (if known)</sup> /NMM/ <sup>US-</sup> 5807741 Brown, et al. 9-15-1998 <sup>US-</sup> 5932449 8-31-1999 Emanuel, et al. /NMM/ US-2002155114 10-24-2002 Marks, et al /NMM/ US-US-US-บร-บร-US-US-US-US-US-US-US-US-US-US-

Examiner Initials*	Cite No.1	Foreign Patent Document	GN PATENT DOCU Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	_
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Of Relevant rigules Appear	Ë
						L
						╁
						۲

Examiner Signature	/N. M. Minnifield/ (02/06/2009)	Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND** TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-08)

Approved for use through 09/30/2008. OMD 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE n Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Officer the Paperwork Reduction Act of 1999, he person			CLOR 1000, III polatilo a.	Complete if Known		
Substitu	te for form 1449/PTO			Application Number	10/632,706	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	August 1, 2003			
		First Named Inventor	Marks, et al			
				Art Unit		
(Use as many sheets as necessary)				Examiner Name		
Sheet	2	of	2	Attorney Docket Number	UCSF-400CIP	

Examiner nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/NMM/ 8		AMERSDORFER, et al., Molecular characterization of murine humoral immune response to botulinum neurotoxin type AInfect. Immun., Sep 1997, 3743-3752, Vol 65, No. 9.	
000000000000000000000000000000000000000		CHEN, et al., Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms, Infect Immun. 1997 May; 65(5): 1626–1630.	
000000000000000000000000000000000000000		FERREIRA, et al., Monoclonal antibody to type F Clostridium botulinum toxin, Appl Environ Microbiol. 1990 March; 56(3): 808-811.	
000000000000000000000000000000000000000		KOZAKI,et al., The use of monoclonal antibodies to analyze the structure of Clostridium botulinum type E derivative toxin, Infect Immun. 1986 June; 52(3): 786–791.	,
, , , , , , , , , , , , , , , , , , ,		MULLANEY, et al., Epitope Mapping of Neutralizing Botulinum Neurotoxin A. Antibodies by Phage Display. B. P., Inf. Immun. 69:6511-6514, 2001.	
200000000000000000000000000000000000000		NOWALOWSKI, et al., Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody, PNAS August 20, 2002 vol. 99 no. 17 11346-11350.	
000000000000000000000000000000000000000		OGUMA, et al., Four different monoclonal antibodies against type C1 toxin of Clostridium botulinum, Infect Immun. 1982 October; 38(1): 14-20.	
50000000000000000000000000000000000000		OGUMA, et al., Analysis of antigenicity of Clostridium botulinum type C1 and D toxins by polyclonal and monoclonal antibodies, Infect Immun. 1984 February; 43(2): 584–588.	
		SHONE,et al., Monoclonal antibody-based immunoassay for type A Clostridium botulinum toxin is comparable to the mouse bioassay, Appl Environ Microbiol. 1985 July; 50(1): 63-67	
/NMM/	-	TSUZUKI, et al., Establishment of a monoclonal antibody recognizing an antigenic site common to Clostridium botulinum type B,, Infect Immun. 1988 April; 56(4): 898–902.	

Everminer	
Examiner   /N. M. Minnifield/ (02/06/2009)	te l
	nsidered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 36 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-08)

Approved for use through 09/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
D a collection of information unless it contains a valid OMB control number.

	Complete if Known		
Substitute for form 1449/PTO	Application Number	10/632,706	
INFORMATION DISCLOSURE	Filing Date	August 1, 2003	
STATEMENT BY APPLICANT	First Named Inventor	Marks, et al	
_	Art Unit		
(Use as many sheets as necessary)	Examiner Name		
Sheet 3 of 3	Attorney Docket Number	UCSF-400CIP	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/NMM/		WU, et al., Characterization of Neutralizing Antibodies and Identification of Neutralizing, Applied and Environmental Microbiology, July 2001, p. 3201-3207, Vol. 67, No. 7.	
	4		

Evaminer (A) 44 A 5 - if - L// (00/05/0500)	
Examiner /N. M. Minnifield/ (02/06/2009)  Signature Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## **Privacy Act Statement**

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of
  presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to
  opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.